NicOx SA, an international ophthalmology company, has announced a significant new partnership with Kowa Company, Ltd., a global pharmaceutical firm based in Japan. This agreement, valued at up to €191.5 million, grants Kowa exclusive rights to develop and commercialize NicOx's glaucoma treatment, NCX 470, in the U.S. and other territories worldwide, except for Japan, China, Korea, and Southeast Asia. The deal includes an upfront payment of €7.5 million to NicOx and potential development and commercial milestones contingent on the results of the Denali Phase 3 trial. Kowa will also cover the U.S. NDA filing costs and future development expenses. This collaboration marks a strategic expansion of NicOx's global reach and financial flexibility, allowing the company to explore further growth opportunities in the ophthalmology sector.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.